Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering Gets CNS As Second Therapeutic “Corner” Via Organon Acquisition

Executive Summary

Schering-Plough's planned acquisition of Organon would provide Schering with the entrée into the central nervous system marketplace it has been seeking

You may also be interested in...



Schering Telescope Points To 5 R&D “Stars,” But TRA Shines Brightest

Schering-Plough's investigational thrombin receptor antagonist has the potential to be a transformative commercial opportunity for the drug maker. The product is one of five pipeline "stars" management highlighted during an R&D update Nov. 24, and one investors are keeping an especially close eye on

Schering Points To 5 R&D "Stars," But Antithrombotic Shines Brightest

Schering-Plough's investigational thrombin receptor antagonist has the potential to be a transformative commercial opportunity for the drug maker. The product is one of five pipeline "stars" management highlighted during an R&D update Nov. 24, and one investors are keeping an especially close eye on

Schering Telescope Points To 5 R&D “Stars,” But TRA Shines Brightest

Schering-Plough's investigational thrombin receptor antagonist has the potential to be a transformative commercial opportunity for the drug maker. The product is one of five pipeline "stars" management highlighted during an R&D update Nov. 24, and one investors are keeping an especially close eye on

Related Content

UsernamePublicRestriction

Register

PS048162

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel